ADNI

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究将测试序列磁共振成像(MRI)、正电子发射断层扫描(PET)、其他生物标志物以及临床和神经心理学评估是否可以结合起来衡量轻度认知障碍(MCI)和早期阿尔茨海默病(AD)的进展。通过研究MCI和AD患者和健康人的脑图像变化获得的信息，以及其他评估工具，将被用来确定衡量MCI和AD患者治疗效果的最佳方法。 大约800名年龄在55岁到90岁之间的参与者将被招募参加这项研究：400名MCI患者，200名早期AD患者和200名正常对照。MCI患者和正常对照组随访3年，AD患者随访2年。每隔6个月，所有参与者都将在每次扫描时被亲自看到或联系。所有参与者都将接受重复扫描，每次扫描时将收集血液和尿液生物标记物。所有患者都将被问及是否愿意在基线和第一年接受腰椎穿刺术，目标是最低20%，每组最多50%提供脑脊液样本以供分析和存储，以供未来分析。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will test whether serial magnetic imaging(MRI), positron emission tomography(PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment(MCI) and early alzheimer's disease(AD). The information obtained by studying changes in the brain images of MCI and AD patients and healthy individuals, as well as other assessement tools, will be used to determine the best methods for measuring treatment effects in patients MCI and AD. Aproximately 800 participants, ranging in age 55 to 90, will be recruited for the study: 400 patients with MCI, 200 with early AD, and 200 normal controls. Patients with MCI and normal controls will be followed for 3 years, and those with AD will be followed for 2 years. At 6-month intervals all participants will be seen in person or contacted at the time of each scan. All participant will undergo repeated scanning and blood and urine biomarkers will be collected at the time of each scan. All patients will be asked if they are willing to undergo lumbar puncture at baseline and year one, with the goal of a minimum of 20% and as many as 50% of each group providing CSF samples for analysis and storage for future analyses.